As we head into BIO 2025 in Boston, our teams are closely watching trends in biotech and how those affect financings, business development, IP protection, risk, and litigation strategy. Here are eight key trends we’re...more
6/10/2025
/ Artificial Intelligence ,
Biotechnology ,
Business Development ,
Clinical Trials ,
Data Privacy ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Life Sciences ,
Litigation Strategies ,
Medical Research ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Research and Development ,
Risk Management ,
Scientific Research ,
Sustainability ,
Vaccinations
Life sciences M&A comes with unique challenges that require thoughtful and creative structuring. Bridging valuation gaps between buyers and sellers and navigating regulatory scrutiny need careful planning....more
For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword....more
1/6/2025
/ Capital Raising ,
Clinical Trials ,
Corporate Governance ,
Disclosure Requirements ,
Initial Public Offering (IPO) ,
Investors ,
Life Sciences ,
Material Nonpublic Information ,
Medical Research ,
Pharmaceutical Industry ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies
When it comes to disclosing clinical trial data in the biotechnology arena, in particular for public biotech companies, timing is everything. Disclosures are not just about when to reveal the information, but also what is...more
1/6/2025
/ Annual Reports ,
Biotechnology ,
Clinical Trials ,
Corporate Governance ,
Disclosure Requirements ,
Financial Industry Regulatory Authority (FINRA) ,
Food and Drug Administration (FDA) ,
Form 10-K ,
Form 10-Q ,
Life Sciences ,
Pharmaceutical Industry ,
Securities and Exchange Commission (SEC)
The life sciences sector will likely be one of the major drivers in what some analysts predict as the beginning of the largest economic expansion in recent history. ...more
3/25/2021
/ Coronavirus/COVID-19 ,
Digital Health ,
Infectious Diseases ,
Initial Public Offering (IPO) ,
Innovative Technology ,
Investment Opportunities ,
Life Sciences ,
Pharmaceutical Industry ,
Special Purpose Acquisition Companies (SPACs) ,
Startups ,
Vaccinations ,
Venture Capital
Survey Results -
Life Sciences and Tech IPOs Continued Hot Streak in Second Half -
The life sciences and technology IPO markets continued their strong performance in the second half of 2018, notwithstanding significant...more